Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation
المؤلفون المشاركون
Hur, Dae Young
Kim, Kyung Eun
Park, Sunyoung
Cheon, Soyoung
Kim, Dong Yeon
Cho, Dae Jin
Park, Jeong Min
Park, Hyun Jeong
Cho, Daeho
المصدر
Journal of Immunology Research
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-12-31
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Radotinib (Supect™) was developed to treat chronic myeloid leukemia (CML) as a BCR-ABL1 tyrosine kinase inhibitor (TKI).
Other TKIs, including imatinib and nilotinib, were also developed for treatment of CML, and recent studies were increasing about the therapeutic effects of other TKIs on solid tumors.
However, the effect of radotinib on solid tumors has not yet been investigated.
In this study, radotinib killed CML cell line K562 directly; however, radotinib did not enhance NK cell cytotoxicity against K562 cells.
Because K562 is known as a Fas-negative cell line, we investigated whether radotinib could regulate cell cytotoxicity against various Fas-expressing solid cancer cell lines.
Radotinib dramatically increased NK cell cytotoxicity against various Fas-expressing solid cancer cells, including lung, breast, and melanoma cells.
Additionally, the efficiency of radotinib-enhanced cytotoxicity was lower in Fas siRNA-transfected cells than in negative controls, suggesting that Fas signaling might be involved in the radotinib-enhanced NK cell cytotoxicity.
This study provides the first evidence that radotinib could be used as an effective and strong therapeutic to treat solid tumors via upregulation of NK cell cytotoxicity, suggesting that radotinib has indirect killing mechanisms via upregulation of antitumor innate immune responses as well as direct killing activities for CML cells.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kim, Kyung Eun& Park, Sunyoung& Cheon, Soyoung& Kim, Dong Yeon& Cho, Dae Jin& Park, Jeong Min…[et al.]. 2018. Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1193339
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kim, Kyung Eun…[et al.]. Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation. Journal of Immunology Research No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1193339
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kim, Kyung Eun& Park, Sunyoung& Cheon, Soyoung& Kim, Dong Yeon& Cho, Dae Jin& Park, Jeong Min…[et al.]. Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1193339
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1193339
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر